Abstract: Objective To assess the efficacy and complications of CT-guided percutaneous ¹²⁵I seed implantation brachytherapy in the treatment of stage Ⅲ non-small-cell lung cancer(NSCLC). Methods Clinical date of 19 stage Ⅲ NSCLC cases were retrospectively analyzed. All cases were pathologically confirmed. The median age of patients was 57 years. Preoperative chest enhanced CT scan was performed to show the location and size of the tumor and its relation with surrounding organs. Hematologic studies were conducted to exclude patients with coagulant or hepatic and renal function abnormality. The treatment planning system(TPS)was used preoperatively to calculate the estimated seed number and distribution. The prescription dose(PD)was 120 Gy. ¹²⁵I seeds were implanted percutaneously under CT guidance and local anesthesia. Follow-up CT scan was performed 1, 3 and 6 months after surgery. Therapeutic effect was evaluated according to response evaluation criteria in solid tumors(RECIST). Results The median volume of tumors was 20 cm³. Local tumor control rate(CR+PR+SD)was 94.7%(18/19), 94.7%(18/19), 87.5% 山 东 大 学 学 报 (医 学 版)55卷2期 -戴建建,等.CT引导下¹²⁵I粒子植入治疗Ⅲ期非小细胞肺癌疗效与并发症的临床观察 \=-(14/16), 83.3%(10/12), 85.7%(6/7)and 83.3%(5/6)1, 2, 5, 7, 8 and 9 months after operation. The median follow-up was 7 months(4-24), and the median time to progression was 7 months(2-21). No major complications were observed. Minor complications included pulmonary hemorrhage(n=7, 37%), subcutaneous hematoma(n=1, 5%), mild pneumothorax(n=1, 5%), closed drainage of thoracic cavity(n=5, 26%), late-onset pneumothorax(n=1, 5%), hemoptysis(n=3, 16%), and subcutaneous emphysema(n=1, 5%). Conclusion Safe and effective, CT-guided percutaneous ¹²⁵I seed implantation brachytherapy can serve as an adjuvant option in the treatment of stage Ⅲ NSCLC.

Key words: ¹²⁵I seed, Non-small-cell lung cancer, Computed tomography, Brachytherapy